Wakamoto Pharmaceutical Co.,Ltd.

Tokyo Stock Exchange 4512.T

Wakamoto Pharmaceutical Co.,Ltd. Revenue Per Share for the year ending March 31, 2024: USD 1.47

Wakamoto Pharmaceutical Co.,Ltd. Revenue Per Share is USD 1.47 for the year ending March 31, 2024, a -21.56% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Wakamoto Pharmaceutical Co.,Ltd. Revenue Per Share for the year ending March 31, 2023 was USD 1.88, a -5.34% change year over year.
Wakamoto Pharmaceutical Co.,Ltd. Revenue Per Share for the year ending March 31, 2022 was USD 1.98, a -14.26% change year over year.
Wakamoto Pharmaceutical Co.,Ltd. Revenue Per Share for the year ending March 31, 2021 was USD 2.31, a -20.89% change year over year.
Wakamoto Pharmaceutical Co.,Ltd. Revenue Per Share for the year ending March 31, 2020 was USD 2.93, a 4.80% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Tokyo Stock Exchange: 4512.T

Wakamoto Pharmaceutical Co.,Ltd.

CEO	Mr. Arata Igarashi
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	2-2-2, Nihonbashi Honcho
Employees	403
Sector	Health Care
Industries Pharmaceuticals

Description

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years